Biliary dyskinesia in children with irritable bowel syndrome: overlap syndrome. The search for a modern approach to the treatment of abdominal pain syndrome

Objective. To optimize therapeutic approaches to the treatment of abdominal pain syndrome in children with overlapping syndrome of biliary dyskinesia + irritable bowel syndrome.

Characteristics of children and research methods. The study included 309 children aged from 13 to 17 years. Irritable bowel syndrome was diagnosed in 76 (24.6%) patients in accordance with the Rome IV revision criteria and the results of laboratory and instrumental studies. 45 (59.2%) patients had a variant of the syndrome with constipation, 19 (25%) – a variant with diarrhea, 12 (15.8%) – a mixed variant (alternating constipation with diarrhea). Biliary pain was detected in 58 (76.3%) patients, including 34 (44.7%) patients with constipation, 13 (17.1%) with diarrhea variants and 11 (14.5%) with mixed option. The researchers used two treatment options: trimebutin (Trimedat, ValentaPharm, Russia) in an age dosage for 28 days (main group) and papaverine in an age dosage for 4 weeks (comparison group).

Results. The main group demonstrated a more pronounced decrease in the intensity of abdominal pain associated with both irritable bowel syndrome and biliary dyskinesia. Differences between treatment results in the main and control groups are statistically significant (p<0.01). During the treatment period there were no cases of side effects in the main group, the differences in the frequency of side effects between the main group and the comparison group are statistically significant. (p=0.01).

Conclusion. Correction of abdominal pain with trimebutin significantly exceeds the effectiveness of standard antispasmodic therapy in the treatment of overlap syndrome of irritable bowel syndrome + biliary dyskinesia. Trimebutin therapy is safe and can be recommended as a fairly effective method of treating children with overlap syndrome.

1. Boeckxstaens G., Camilleri M., Sifrim D., Houghton L.A., Elsenbruch S., Lindberg G. et al. Fundamentals of Neurogastroenterology: Physiology/Motility – Sensation. Gastroenterology 2016; 150(6): 221–223. DOI: 10.1053/j.gastro.2016.02.030

2. Shadi S., Christie J. Functional dyspepsia in review: Pathophysiology and challenges in the diagnosis and management due to coexisting gastroesophageal reflux disease and irritable bowel syndrome. Gastroenterol Res Pract 2013; 2013: 351086. DOI: 10.1155/2013/351086

3. Carabotti M., Scirocco A., Maselli M., Severi C. The gut-brain axis: interactions between enteric microbiota, central and enteric nervous systems. Gastroenterol 2015; 28(2): 203–209

4. Bel’mer S.V., Havkin A.I., Pechkurov D.V. Functional disorders of the digestive system in children. The principles of diagnosis and treatment (in the light of Rome IV criteria). M.: GEOTAR-Media, 2018; 160. (in Russ.)

5. Minushkin O.N. Pharmacological approaches to the treatment of combined functional pathology (biliary and intestinal). Meditsinkii sovet 2018; (14): 78–82. (in Russ.)

6. Ivashkin V.T., Maev I.V., Shul`pekova Yu.O., Baranskaja E.K. Clinical guidelines of the Russian Gastroenterological Association for the diagnosis and treatment of biliary dyskinesia. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii 2018; 28(3): 63–80. (in Russ.)

7. Park H. Functional gastrointestinal disorders and overlap syndrome in Korea J Gastroenterol Hepatol 2011; 26(3 Suppl): 12–14. DOI: 10.1111/j.1440-1746.2011.06644.x

8. Talley N., Locke G., Herrick L., Silvernail V.M., Prather C.M., Lacy B. et al. Functional Dyspepsia Treatment Trial (FDTT): a double-blind, randomized, placebo-controlled trial of antidepressants in functional dyspepsia, evaluating symptoms, psychopathology pathophysiology and pharmacogenetics. Contemp Clin Trials 2012; 3: 523–533. DOI: 10.1016/j.cct.2012.02.002

9. Ghoshal U., Abraham P., Bhatt C., Choudhuri G., Bhatia S.J., Shenoy K.T. et al. Epidemiological and clinical profile of irritable bowel syndrome in India: report of the Indian Society of Gastroenterology task force. Indian J Gastroenterol 2008; 27(1): 22–28

10. Drossman D., Hasler W. Rome-IV Functional GI disorders: disorders of gut-brain interaction. Gastroenterology 2016; 150(6): 1257–1261. DOI: 10.1053/j.gastro.2016.03.035

11. Von Wulffen M., Talley N.J., Hammer J., McMaster J., Rich G., Shah A. et al. Overlap of Irritable Bowel Syndrome and Functional Dyspepsia in the Clinical Setting: Prevalence and Risk Factors. Dig Dis Sci 2018; 64: 480–486. DOI: 10.1007/s10620-018-5343-6

12. Bortoli N., Tolone S., Frazzoni M., Martinucci I., Sgherri G., Albano E. et al. Gastroesophageal reflux disease, functional dyspepsia and irritable bowel syndrome: common overlapping gastrointestinal disorders. Ann Gastroenterol 2018; 31(6): 639–648. DOI: 10.20524/aog.2018.0314

13. Ford A., Marwaha A., Lim A., Moayyedi P. Systematic review and meta-analysis of the prevalence of irritable bowel syndrome in individuals with dyspepsia. Clin Gastroenterol Hepatol 2010; 8(5): 401–409. DOI: 10.1016/j.cgh.2009.07.020

14. Rasmussen S., Jensen T., Henriksen S., Haastrup P.F., Larsen P.V., Søndergaard J. et al. Overlap of symptoms of gastroesophageal reflux disease, dyspepsia and irritable bowel syndrome in the general population. Scand J Gastroenterol 2015 ;50(2): 162–169. DOI: 10.3109/00365521.2014.983157

15. Osipenko M.F., But-Gusaim V.I., Voloshina N.B., Bikbulatova E.F. Overlap-syndrome: irritable bowel syndrome and functional disorders of the biliary tract. Sibirskii meditsinskii zhurnal 2008; 5: 21–26. (in Russ.)

16. Guberngric N.B. Chronic abdominal pain. Biliary pain. Pain in liver disease. M.: Medpraktika-M, 2007: 420. (in Russ.)

17. Dodds W.J, Groh W.J, Darweesh R.M. Sonographic measurement of gallbladder volume. Am J Roentgenol 1985;145(5): 1009–1011. DOI: 10.2214/ajr.145.5.1009

18. Garrigues V., Ponce J., Cano C., Hojgaard L., Funch-Jensen P. Comparison of the Dynamics of Bile Emptying by Quantitative Hepatobiliary Scintigraphy Before and After Cholecystectomy in Patients With Uncomplicated Gallstone Disease. Dig Dis Sci 1992; 37: 101–104. DOI: 10.1097/00003072-199909000-00002

19. Minushkin O.N. Biliary dysfunction, definition, diagnosis, treatment, modern view on the problem. Meditsinkii sovet 2015;(17):88–95. (in Russ.)

20. Aziz I., Palsson O., Törnblom H., Sperber A.D., Whitehead W.E., Simrén M. Epidemiology, clinical characteristics, and associations for symptom-based Rome IV functional dyspepsia in adults in the USA, Canada, and the UK: a cross-sectional population-based study. Lancet Gastroenterol Hepatol 2018; 3(4): 252–262. DOI: 10.1016/S2468-1253(18)30003-7

21. Eusebi L., Ratnakumaran R., Bazzoli F., Ford A. Prevalence of Dyspepsia in Individuals With Gastroesophageal Reflux-Type Symptoms in the Community: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2018; 16(1): 39–48. DOI: 10.1016/j.cgh.2017.07.041

22. Althaus A., Broicher W., Wittkamp P., Andresen V., Lohse A.W., Löwe B. Determinants and frequency of irritable bowel syndrome in a German sample. Z Gastroenterol 2016; 54(3): 217–225. DOI: 10.1055/s-0041-106856

23. Van Oudenhove L., Crowell M., Drossman D., Halpert A.D., Keefer L., Lackner J.M. et al. Biopsychosocial Aspects of Functional Gastrointestinal Disorders. Gastroenterology 2016; 150(6): 1355–1367. DOI: 10.1053/j.gastro.2016.02.027

24. Liddle R. Cholecystokinin. In Gut Peptides: biochemistry and physiology. Editors J.H. Walsh, G.J. Dockray. New York: Raven Press. 1994; 175–216

25. Hand K.V., Bruen C.M., O’Halloran F., Giblin L., Green B.D. Acute and chronic effects of dietary fatty acids on cholecystokinin expression, storage and secretion in enteroendocrine STC-1 cell. Mol Nutr Food Res 2010; 54(1): 93–103. DOI: 10.1002/mnfr.200900343

26. Owyang С., Logsdon С. New insights into neurohormonal regulation of pancreatic secretion. Gastroenterology 2004; 127(3): 957–969. DOI: 10.1053/j.gastro.2004.05.002

27. Brun R., Kuo B. Functional dyspepsia. Therap Adv Gastroenterol 2010; 3(3): 145–164. DOI: 10.1177/1756283X10362639

28. Yamawaki H., Futagami S., Wakabayashi M., Sakasegawa N., Agawa S., Higuchi K. et al. Management of functional dyspepsia: state of the art and emerging therapies. Ther Adv Chronic Dis 2018; 9 (1): 23–32. DOI: 10.1177/2040622317725479

29. Tomita T., Oshima T., Miwa H. New Approaches to Diagnosis and Treatment of Functional Dyspepsia. Curr Gastroenterol Rep 2018; 20(12): 55. DOI: 10.1007/s11894-018-0663-4

30. Simrén M., Tack J. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol 2018; 15(10): 589–605. DOI: 10.1038/s41575-018-0034-5

31. Ivashkin V.T., Drapkina O.M. Possibilities of using trimebutin in the treatment of patients with irritable bowel syndrome. Rossiiskii zhurnal gastroenterologii, gepatologii, koloproktologii 2008; 5: 12–6. (in Russ.)

32. Bel’mer S.V., Kovalenko A.A., Gasilina T.V., Akopjan A.N., Narinskaja N.M. Possibilities of using trimebutin in the treatment of patients with irritable bowel syndrome. Lechashchii vrach. 2012; 2: 68–72. (in Russ.)

33. Havkin A.I. Antroduodenal motor disorders: approaches to correction. Trudnyi patsient. 2012; 10:8–9. (in Russ.)

34. Bel’mer S.V., Gasilina T.V., Kovalenko A.A., Karpina L.M. Modern ways of correction of functional disorders of the digestive system in children. Voprosy detskoi dietologii 2011;2:10–14. (in Russ.)